 Histone-Lysine N-Methyltransferase
"Histone-Lysine N-Methyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. EC 2.1.1.43.
| Descriptor ID |
D011495
|
| MeSH Number(s) |
D08.811.913.555.500.800.400
|
| Concept/Terms |
Histone-Lysine N-Methyltransferase- Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase
- N-Methyltransferase, Histone-Lysine
- Protein Methylase III
- Histone-Lysine Methyltransferase
- Histone Lysine Methyltransferase
- Methyltransferase, Histone-Lysine
- Protein Lysine Methyltransferase
- Methyltransferase, Protein Lysine
- Protein Methyltransferase III
|
Below are MeSH descriptors whose meaning is more general than "Histone-Lysine N-Methyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Histone-Lysine N-Methyltransferase".
This graph shows the total number of publications written about "Histone-Lysine N-Methyltransferase" by people in this website by year, and whether "Histone-Lysine N-Methyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 3 | 2 | 5 | | 2013 | 2 | 4 | 6 | | 2014 | 2 | 0 | 2 | | 2015 | 5 | 0 | 5 | | 2016 | 9 | 3 | 12 | | 2017 | 3 | 2 | 5 | | 2018 | 3 | 0 | 3 | | 2019 | 4 | 0 | 4 | | 2020 | 1 | 0 | 1 | | 2021 | 7 | 3 | 10 | | 2023 | 1 | 0 | 1 | | 2024 | 6 | 3 | 9 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone-Lysine N-Methyltransferase" by people in Profiles.
-
Vann KR, Sharma R, Hsu CC, Devoucoux M, Tencer AH, Zeng L, Lin K, Zhu L, Li Q, Lachance C, Ospina RR, Tong Q, Cheung KL, Yang S, Biswas S, Xuan H, Gatchalian J, Alamillo L, Wang J, Jang SM, Klein BJ, Lu Y, Ernst P, Strahl BD, Rothbart SB, Walsh MJ, Cleary ML, C?t? J, Shi X, Zhou MM, Kutateladze TG. Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation. Nat Commun. 2025 Mar 06; 16(1):2235.
-
Biswas S, Lee JE, Xie G, Masclef L, Ren Z, C?t? J, Affar EB, Ge K, Kutateladze TG. Colorectal cancer hot spot mutations attenuate the ASXL-MLL4 interaction. J Biol Chem. 2025 Mar; 301(3):108333.
-
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. Mol Cancer Res. 2024 12 03; 22(12):1117-1127.
-
Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Haematologica. 2024 Dec 01; 109(12):3918-3927.
-
Neeman B, Sudhakar S, Biswas A, Rosenblum J, Sidpra J, D'Arco F, L?bel U, G?mez-Chiari M, Serrano M, Bolasell M, Reddy K, Ben-Sira L, Zakzouk R, Al-Hashem A, Mirsky DM, Patel R, Radhakrishnan R, Shekdar K, Whitehead MT, Mankad K. Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development. AJNR Am J Neuroradiol. 2024 Oct 03; 45(10):1570-1577.
-
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84.
-
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. Nat Commun. 2024 Aug 08; 15(1):6755.
-
Zhang Y, Xie G, Lee JE, Zandian M, Sudarshan D, Estavoyer B, Benz C, Viita T, Asgaritarghi G, Lachance C, Messmer C, Simonetti L, Sinha VK, Lambert JP, Chen YW, Wang SP, Ivarsson Y, Affar EB, C?t? J, Ge K, Kutateladze TG. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers. Nat Commun. 2024 Jun 07; 15(1):4883.
-
Yokoyama A, Niida H, Kutateladze TG, C?t? J. HBO1, a MYSTerious KAT and its links to cancer. Biochim Biophys Acta Gene Regul Mech. 2024 Sep; 1867(3):195045.
-
Becht DC, Mohid SA, Lee JE, Zandian M, Benz C, Biswas S, Sinha VK, Ivarsson Y, Ge K, Zhang Y, Kutateladze TG. MLL4 binds TET3. Structure. 2024 Jun 06; 32(6):706-714.e3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|